Health Care & Life Sciences » Biotechnology | Asterias Biotherapeutics Inc.

Asterias Biotherapeutics Inc.

Asterias Biotherapeutics Inc.
Stock Exchange NYSE
EPS
$0.43
Market Cap
$74.94 M
Shares Outstanding
55.51 M
Public Float
33.08 M

Profile

Address
6300 Dumbarton Circle
Fremont California 94555
United States
Employees -
Website http://www.asteriasbiotherapeutics.com
Updated 09/14/2018
Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer.

Financials

View All
Created with Highcharts 5.0.14Asterias Biotherapeutics Inc.Net Income. Fiscal year is January-December. All values USD Thousands.22 37922 37910 09710 09715 00315 00335 48935 48928 37228 37220132014201520162017010k20k30k40k
Created with Highcharts 5.0.14Asterias Biotherapeutics Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.001 2231 2233 5823 5826 9546 9544 0424 0422013201420152016201702k4k6k8k

Michael H. Mulroy
President, Chief Executive Officer & Director
Stephen Lahue Cartt
Director